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Abstract
Background—Prior work on the link between blood-based biomarkers and cognitive status has 
largely been based on dichotomous classifications rather than detailed neuropsychological 
functioning. The current project was designed to create serum-based biomarker algorithms that 
predict neuropsychological test performance.
Methods—A battery of neuropsychological measures was administered. Random forest analyses 
were utilized to create neuropsychological test-specific biomarker risk scores in a training set that 
were entered into linear regression models predicting the respective test scores in the test set. 
Serum multiplex biomarker data were analyzed on 108 proteins from 395 participants (197 AD 
cases and 198 controls) from the Texas Alzheimer’s Research and Care Consortium.
Results—The biomarker risk scores were significant predictors (p<0.05) of scores on all 
neuropsychological tests. With the exception of premorbid intellectual status (6.6%), the 
biomarker risk scores alone accounted for a minimum of 12.9% of the variance in 
neuropsychological scores. Biomarker algorithms (biomarker risk scores + demographics) 
accounted for substantially more variance in scores. Review of the variable importance plots 
indicated differential patterns of biomarker significance for each test, suggesting the possibility of 
domain-specific biomarker algorithms.
Conclusions—Our findings provide proof-of-concept for a novel area of scientific discovery, 
which we term “molecular neuropsychology.”
Keywords
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Background
The long-standing search for accurate biomarkers from many conditions/diseases impacting 
neuropsychological functioning include, but are not limited to, Alzheimer’s disease (AD)[1–
4], traumatic brain injury (TBI) [5, 6], schizophrenia [7, 8], alcohol use/abuse [9], and mood 
disorders [9–11]. For example, we recently created a serum-based biomarker algorithm that 
yielded excellent diagnostic accuracy in separating AD cases from controls [1, 12, 13]. 
Significant advancements have been made though analyses of blood, cerebrospinal fluid, 
and advanced neuroimaging modalities, and it is likely that combining assessment 
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modalities (e.g. biomarkers + clinical data + demographics) will yield better results than any 
single modality [1, 12, 14–16].
While animal model work has begun to examine proteomic and genomic methods for 
discovering potential pathways and biomarkers of specific cognitive abilities [17], the 
majority of human biomarker research to date has been based on dichotomous group 
classifications (case vs. control) rather than linear constructs upon which clinical decisions 
and/or diagnoses of cognitive dysfunction are based (i.e. neuropsychological testing). While 
others are examining the link between biomarkers of disease states (e.g. AD) and cognitive 
functioning [18], biomarkers associated with neuropsychological test performance as 
continuous variables could provide novel opportunities to study these conditions/diseases[4]. 
For example, in our prior work we did not show a significant difference in serum BDNF 
levels between AD cases and controls; however, serum BDNF levels were specifically 
associated with memory performance among AD cases[4]. Blood-based biomarkers are 
preferable as they are more cost and time efficient and more conveniently acquired than CSF 
or neuroimaging [19]. An additional advantage of proteomic approaches to biomarker 
identification is the potential to discover alterations at the protein level that may be closely 
related to the pathophysiological process(es) underlying complex conditions and disease 
states [9]. The purpose of the present study was to take a first step towards creating serum-
based biomarker algorithms of neuropsychological functioning. This proof of concept 
project provides a platform for a novel field of scientific discovery, which we term 
“molecular neuropsychology.”
Even though there are currently no available blood-based biomarkers of neuropsychological 
functioning, there is a growing literature linking specific blood biomarkers to 
neuropsychological performance. In the instance of AD, we analyzed data from a sample of 
399 participants (198 AD, 201 controls) enrolled in the Texas Alzheimer’s Research & Care 
Consortium (TARCC) and found that serum brain-derived neurotrophic factor (BDNF) 
levels were significantly associated with poorer immediate and delayed visual and verbal 
memory scores[4] among AD cases but not controls. We failed to find a significant link 
between C-reactive protein (CRP) levels and cognition (Mini-Mental State Examination, 
MMSE[20]) scores among a sample of 192 AD cases and 174 controls, though increased 
CRP levels were associated with disease severity [21]. On the other hand, Noble and 
colleagues [21] analyzed data on 1,331 participants of the WHICAP study and found CRP 
levels (highest tertile versus lowest tertile) to be specifically associated with impairment in 
memory and visuospatial abilities but not language or executive functioning. Additionally, it 
was noted that ApoEμ4 carriers were most likely to demonstrate impairment in memory. 
Wilson et al [22] examined a sample of controls, MCI and dementia cases (AD and non-AD 
dementias) with CDR global scores ranging from 0 to 3. These authors found that 
Repeatable Battery for Neuropsychological Status (RBANS)[23] Language, Immediate and 
Delayed Memory Indices were significantly related to plasma Anti-RAGE immunoglobulins 
(IgGs) and Anti-Aβ IgGs concentrations. Interestingly, Igμ, a heavy chain of 
immunoglobulin M (IgM) was part of the protein profile recently identified in serum among 
schizophrenia patients [8] and immunoglobulins were also part of our AD diagnostic 
algorithm (Appendix 1 of O’Bryant et al[1]). While neuropsychological testing was not 
conducted as part of the schizophrenia project, this work suggests a role of immunoglobulins 
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in neuropsychological functioning across multiple disease states. When examining the 
outcome of children suffering from traumatic brain injury with and without histories of 
abuse, Beers et al [24] found serum concentrations of neuron-specific enolase (NSE), 
S100B, and myelin-basic protein (MBP) were related to six-month functional and cognitive 
outcomes. In a sample of 998 non-demented community-dwelling adults of the Longitudinal 
Aging Study Amsterdam (LASA), Dik and colleagues [25] found that adrenocorticotropic 
hormone (ACT) concentration was significantly associated with delayed verbal recall and 
albumin with MMSE scores. When the sample was restricted to those with MMSE scores 
greater than 21 (suggesting mild to moderate dementia), ACT was also associated with 
processing speed and delayed recall. Next the authors examined only those suspected of 
possible mild cognitive dysfunction (i.e. MMSE scores 21–26) and found that IL-6 and CRP 
were significantly associated with cognitive decline over a three-year period. Despite the 
growing research linking specific blood-based biomarkers and neuropsychological test 
performance (by cognitive domain in many cases) across various conditions and disease 
states, no prior work has attempted to create biomarker algorithms of test-specific 
neuropsychological functioning.
The current study sought to create neuropsychological test-specific biomarker algorithms in 
a cohort of elders with and without cognitive impairment. The ability to create such 
algorithms would have broad reaching applications. We hypothesized that our test-specific 
algorithms would account for significant percentages of the variance in neuropsychological 
performance in the test sample.
Methods
Participants
Participants included 395 individuals (197 AD subjects, 198 controls) enrolled in the Texas 
Alzheimer’s Research & Care Consortium (TARCC). The methodology of the TARCC 
project has been described in detail elsewhere[1, 26]. Briefly, each participant undergoes a 
standardized annual examination at the respective sites, which includes a medical 
evaluation, neuropsychological testing, interview, and blood draw for storage of samples in 
the TARCC biobank. Diagnosis of AD was based on NINCDS-ADRDA criteria[27] 
utilizing consensus review. Controls were subjects without cognitive complaints or medical 
conditions that could impair cognition and who performed within normal limits on 
psychometric assessment. Institutional Review Board approval was obtained at each 
TARCC site and written informed consent was obtained for all participants.
Assays
Non-fasting blood samples were collected into 10mL tiger-top serum-separating tubes. 
Samples were allowed to clot at room temperature for 30 minutes in a vertical position. 
Within one hour of collection, samples were centrifuged for 10 minutes at 2500 × g and 
aliquoted into 1mL cryovial tubes and stored in −80°C freezers. Batched specimens from 
either baseline or year-one follow-up exams were sent frozen to Rules Based Medicine 
(RBM, www.rulesbasedmedicine.com, Austin, TX) where they were thawed for assay 
without additional freeze-thaw cycles using the RBM multiplexed immunoassay human 
O’Bryant et al. Page 4













Multi-Analyte Profile (humanMAP). Individual proteins were quantified with 
immunoassays on colored microspheres. Information regarding the mean, standard 
deviation, least detectable dose (LDD), and inter-run coefficient of variation, are listed in 
Table 1.
Neuropsychological Testing
The TARCC neuropsychology core battery consists of commonly utilized instruments that 
tap a variety of cognitive domains. Specific tests include Digit Span (WAIS-R, WAIS-III, 
WMS-R)[28], Trail Making Test[29], Logical Memory and Visual Reproduction (WMS-R 
and WMS-III)[28], Boston Naming Test (30- and 60-item versions)[29], verbal fluency 
(FAS)[30], Clock Drawing Test[30], the American National Adult Reading Test 
(AMNART)[30], MMSE[20], and the Clinical Dementia Rating scale (CDR)[31]. In order 
to equate scores from digit span and story memory scales, raw scores for all 
neuropsychological tests were converted to scaled scores based on previously published 
normative data [32–34]. For the Boston Naming Test, we recently published an independent 
study demonstrating the psychometric properties of an estimated 60-item BNT score that 
can be calculated from 30-item versions[35]; this estimated 60-item score was calculated for 
all 30-item administrations.
Statistical Analyses
Analyses were performed using R (V 2.10) statistical software[36]. The log transformed and 
then standardized data on each analyte from our AD diagnostic algorithm publication was 
utilized in the current analyses[1]. Random forest (RF) analysis was developed by Breiman 
as an ensemble learning method that utilizes a classification tree as the base classifier[37, 
38]. The RF model has four steps: 1. generate many random subsets (bootstrap samples) 
from the original data; 2. build a decision tree from each random subset; 3. make a 
prediction from each decision tree model; 4. combine the predictions from each individual 
tree model to get the final prediction. The RF model can be used to predict both binary/
categorical outcomes and continuous outcomes. For predicting binary or categorical 
outcomes, the random forest model will build many classification trees, and then combine 
the predictions from individual trees by a majority vote approach. While for predicting 
continuous outcomes, the random forest model will build regression trees [2] instead of 
classification trees, and then use model averaging techniques to combine the predictions 
from individual regression trees. This method has been shown to perform well in many 
classification and prediction scenarios[39, 40], including algorithmic approaches CSF[41], 
EEG[42] and fMRI [43, 44] findings. The random forest prediction model was performed 
using R package randomForest (V 4.5)[37], with all software default settings. TARCC 
participants were randomized into a training set (n=197, AD n=98, control n=99) or a testing 
set (n=198; AD n=99, control n=99) by random number generator. The full list of 108 
serum-based analytes utilized in the algorithm can be found in Appendix 1. A random forest 
(RF) prediction model biomarker risk score was generated for each specific 
neuropsychological test within the training set, which was then entered as predictor variables 
in linear regression models in the test set, with the neuropsychological scale scores as the 
outcome variables; age, gender, and education were entered as covariates. The percentage of 
participants having a diagnosis of diabetes, hyperlipidemia, hypertension, or being obese is 
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presented in Table 2. With the exception of obesity (AD = 13%, controls = 21%), there was 
no significant difference in presence of these conditions between groups. Obesity status was 
not significantly related to neuropsychological test scores and, therefore, none of these 
medical conditions were included in our analyses. Significance was set at p<0.05.
Results and Discussion
Demographic characteristics of the study population are shown in Table 2. The distributions 
of neuropsychological test scores by AD versus control status can be found in Figure 1. The 
relation between the most relevant biomarkers and neuropsychological test scores can be 
found in the heatmap of Figure 2. Online supplemental Figure 3 provides the distributions of 
biomarkers by AD versus control status.
The biomarker risk scores created from the training set were significant predictors of all 
neuropsychological scores in the test set. However, the biomarker risk scores for global 
cognition (MMSE, p<0.001) and disease severity (CDR Global Score p<0.001, CDR Sum of 
Boxes score p<0.001) were among the most powerful. Across the domain of memory, the 
biomarker risk scores were strong predictors of test performance in both visual (Visual 
Reproduction I p<0.001, Visual Reproduction II p<0.001) and verbal domains (Logical 
Memory I p<0.001, Logical Memory II p<0.001) (see Table 3 for all results).
The amount of variance in test scores accounted for by the biomarker risk scores alone 
ranged from 6.6% to 47.3%. In fact, the biomarker risk score accounted for 43.9% of the 
variance in immediate verbal memory (WMS LM I) and 47.3% in delayed verbal memory 
(WMS LM II), 30.9% of the variance in immediate visual memory (WMS VR I) and 41.2% 
of the variance in delayed visual memory (WMS VR II). The amount of variance accounted 
for by each test-specific biomarker risk score, independent of age, gender and education is 
presented in Table 3. Prior work has demonstrated that age, gender, and education influence 
neuropsychological test performance [29, 30] and it is standard practice to use these factors 
in creating normative references. Therefore, we also examined the variance accounted for in 
neuropsychological test scores by test-specific biomarker algorithms (biomarker risk scores 
+ age, gender and education). The biomarker algorithms accounted for large portions of 
variance in neuropsychological test scores including 49.4%–51.2% of the variance in verbal 
memory, 33.5%–44.7% of the variance in visual memory, 26.5%–36.7% of the variance in 
language, 27.2%–32.0% of the variance in executive functioning, and 30.1% of the variance 
in processing speed. We also created a biomarker algorithm that accounted for 41.6%–
42.6% of the variance in disease severity (see Table 3). The amount of additional variance 
accounted for by inclusion of demographic factors varied by test and was smallest for 
memory measures.
Lastly, we reviewed the variable importance plots. Random forests generate variable 
importance plots based on the number of times each variable is selected by all individual 
trees in the ensemble (naive variable importance) [45]. The Gini importance method, 
utilized in the current study, incorporates a weighted mean of the improvement in the 
splitting criteria of the individual trees produced by each variable [45]. Review of the 
variable importance plots showed that the relative ranking of markers in the algorithm varied 
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by every test-specific biomarker risk score in the analyses. To illustrate this, variable 
importance plots reflecting the top 10 markers contained in the algorithms of tests from four 
different domains (executive functioning, memory, intelligence, and attention) are presented 
in Figures 3 through 6. It is worth noting that the Gini index relies on the assumptions of 
independence, and does not account for the dependency among the features. More advanced 
statistical methods may be need to more accurately access the modeling fit.
Conclusion
We took a novel approach to the search for biomarkers of cognitive functioning by shifting 
the outcome variable from dichotomous categorization of group status (case versus control) 
to a continuous construct of neuropsychological test scores. Here we demonstrate that it is 
possible to create serum-based biomarker algorithms of specific neuropsychological 
function that account for considerable portions of the variance in test scores and that the 
biomarker profiles vary according to cognitive domain. This proof-of-concept work supports 
expanding the search for biomarker mediators of cognitive functioning, which we entitle 
Molecular Neuropsychology.
This work expands on prior work looking at how individual biomarkers are related to 
specific neuropsychological tests, which may have broader utility for understanding and 
predicting cognitive dysfunction. For example, it is possible that biomarker profiles will aid 
in the identification of those at greatest risk cognitive decline. Prior work has demonstrated 
that baseline neuropsychological test scores predict change in status over time as well as 
progression to AD. For example, Musicco and colleagues [46] recently analyzed data on 154 
newly diagnosed AD cases and found that more severe memory and executive functioning 
difficulties at baseline predicted more rapid progression over a two-year follow-up period. 
Examining data from the Vienna Transdanube Aging Study (VITA), Jungwirth et al [47] 
analyzed 5-year longitudinal data to determine what baseline variables best predicted 
incident AD in those without cognitive impairment. These authors found that a combination 
of baseline CERAD Word List Delayed Recall, Trail Making Test part A, presence of the 
ApoE μ4 allele gene, and memory complaints significantly predicted incident AD, with an 
area under the receiver operating characteristic curve (AUC) of 0.91 and a model R2 = 0.43. 
It is possible that combining biomarkers with select cognitive and clinical variables will 
significantly improve the prediction capacity of such models and our group is currently 
working on this possibility. Another advantage of this approach is the possibility of studying 
biological systems that may be of etiological importance. Lastly, a significant amount of 
research has gone into imaging neurological mechanisms of cognitive function/dysfunction. 
The current work may provide the ability to combine biochemical pathway analysis with 
functional neuroimaging methods for a better understanding of the biology of 
neuropsychological dysfunction.
The current results also support the notion that our algorithms may be test-specific based on 
the variable importance plots. In fact, the order of the markers varied across all 
neuropsychological tests (Clock, WMS LM I, AMNART, and Digit Span presented in 
Figures 1–4). While it has been suggested that the variable importance measures from 
random forest analysis can be biased [45], the current findings provide ample proof-of-
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concept for delving further into the investigation of neuropsychological domain-specific 
blood-based biomarker algorithms. While we utilized a broad set of proteins, there are other 
proteins that have been found important that were not included in our multi-plex assays [22]. 
It is certainly possible that better algorithms can be created by utilization of even larger 
protein panels that could then be refined to briefer versions.
There are limitations to the current study. While we utilized a broad range of serum-based 
proteins, it is likely that other markers not included in our assays would contribute 
significantly to building such blood-based biomarker algorithms of neuropsychological 
functioning. Future work should utilize a larger discovery set of biomarkers that can be 
narrowed as necessary. A second limitation to the current study is the brevity of the 
neuropsychological test battery. The TARCC battery consists of commonly used 
neuropsychological instruments; however, it was designed to be brief and does not fully 
assess several domains of cognition (e.g. executive functioning, visuospatial skills). In order 
to thoroughly research the potential of creating serum-based biomarker algorithms of 
neuropsychological tests and/or domains, a more comprehensive battery of tests should be 
implemented. A second limitation to the TARCC battery is the lack of consistency across 
sites with regards to instruments (e.g. WMS-R versus WMS-III). We utilized scale scores in 
order to equate across test versions; however, this remains a limitation to the protocol. Our 
study is also limited by inclusion of only AD cases and normal controls. When examining 
only individuals who have been screened into research projects based on performing 
“normal” or abnormal on cognitive measures creates an inherent bias that reduces the range 
of performance in neuropsychological test scores, as is the case with the TARCC cohort. 
Inclusion of AD cases in the current study enables us to capitalize on a full spectrum of 
cognitive performance. However, AD status was utilized in case selection thereby causing 
some unavoidable circularity. On the other hand, if one enters disease severity (or disease 
status) into the models, the results do not hold, which is likely due to the fact that disease 
severity and degree of neurocognitive deficits are highly confounded. If we analyzed the 
group separately, the current findings do not hold due to this restricted range of scores. The 
advantage of this approach is the ability to have a broad range of cognitive function/
dysfunction; however, additional work is needed to represent a full spectrum of 
neuropsychological status. For example, there is evidence to suggest that biomarkers will 
also be related to exceptional cognitive functioning as demonstrated by Lopez et al [48] who 
found that uromodulin and Compmlement C3 were expressed at higher levels among highly 
intelligent elders when compared to those with lower intelligence.
The current study demonstrates that (1) blood-based biomarkers can be combined to create 
algorithms related to neuropsychological functioning, and (2) biomarker profiles will vary 
according to the cognitive domain being examined. This proof-of-concept work highlights 
the importance of investigating blood-based biomarker profiles of neurosychological 
functioning, which may have clinical utility across a broad range of conditions/populations.
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Distribution of Neuropsychological Test Scores by AD versus normal control
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Heatmap of correlation coefficients between individual biomarkers and neuropsychological 
test scores
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Variable importance plot for the domain of executive functioning
O’Bryant et al. Page 14














Variable importance plot for the domain of memory
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Variable importance plot for the domain of intelligence
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Variable importance plot for the domain of attention
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Table 1
Mean, standard deviation, and least detectable dose for top blood-based markers in algorithms
Mean Std LDD
VCAM-1 799.79 213.14 1.5ng/mL
B2M 2.39 1.04 0.013ug/mL
IL8 22.95 8.87 3.5pg/mL
vWF 38.26 21.32 0.40ug/mL
Eotaxin3 104.13 333.29 70.0pg/mL
TenascinC 957.12 639.29 3.0ng/mL
PPY 192.10 191.66 5.0pg/mL
FAS 8.88 4.11 0.27ng/mL
A2M 1.33 1.06 0.061mg/mL
TPO 6.11 1.83 3.2ng/mL
S100b 0.43 0.32 0.30ng/mL
CKMB 0.36 0.34 0.42ng/mL
SCF 526.85 209.58 56.0pg/mL
EGF-R 4.93 1.14 0.042ng/mL
TNFb 3.50 3.61 46.0pg/mL
AgRP 73.46 130.41 .165ng/mL
G-CSF 10.06 4.84 3.4pg/mL
CRP 3.45 4.52 0.0015ug/mL
NOTE: LDD = least detectable dose
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Table 2
Demographic Characteristics of Sample





CDR SB 3.8 (5.0)









Note: MMSE = Mini-mental Sate Examination; CDR SB = Clinical Dementia Rating scale – Sum of Boxes score; apoE = apolipoprotein € 4 allele
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